Biopharma dealmaking is driven by pressure to top up drug pipelines ahead of major patent expirations later this decade.
Biotech IPO window is opening but big pharma M&A still sets the pace, top bankers tell CNBC
Biopharma dealmaking is driven by pressure to top up drug pipelines ahead of major patent expirations later this decade.
